Investor Presentation Full Year 2021
71
Investor presentation Full year 2021
Haemophilia is a rare disease with severe unmet medical needs
and the market is highly competitive
Number of Low diagnosis and treatment rates
people (000)
500
400
300
200
100
0
People with
haemophilia
within haemophilia
Diagnosed
Haemophilia A ■Haemophilia B
DKK
Sales of recombinant haemophilia products
billion
40
30
30
20
20
10
Novo NordiskⓇ
0
Inhibitor
2016 2020
2016
2020
2016
Haemophilia
with inhibitors
NovoSevenⓇ
Coagil VII
Obizur¹
Haemophilia A
EsperoctⓇ
NovoEight®
2020
Haemophilia B
RefixiaⓇ/RebinynⓇ
Idelvion
Advate/Adynovate
Rixubis
Kogenate/Kovaltry/Jivi
Feiba²
Hemlibra³
Alprolix
Xyntha/Refacto
Benefix
Eloctate/Elocta
Helixate/Afstyla
Hemlibra
Note: The inhibitor segment includes acquired haemophilia patients, patients with low titre inhibitors or with transient
inhibitors, and patients on immune tolerance induction.
Source: World Federation of Haemophilia (WFH) - Annual survey 2018; WFH: Closing the gap - achieving optimal care,
Haemophilia 2012.
1 Obizur only indicated for acquired haemophilia; 2 Plasma-derived; 3 Part of the Hemlibra sales is used for treatment of
haemophilia A patients in 2020
Source: Company reported sales and EvaluateView entire presentation